Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm
03 oct. 2024 12h16 HE
|
KUEHN LAW, PLLC
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Apellis Pharmaceuticals, Inc. (NASDAQ:...
DEADLINE ALERT for EOSE, APLS, and HAYW: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
02 oct. 2023 11h16 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
APLS DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Class Action – APLS
30 sept. 2023 16h46 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
27 sept. 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
25 sept. 2023 12h30 HE
|
Bernstein Liebhard LLP
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)?Did you purchase your shares between January 28,...
DEADLINE ALERT for EOSE, PRTYQ, APLS, and HAYW: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
25 sept. 2023 11h42 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
ROSEN, A LEADING AND RANKED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action – APLS
25 sept. 2023 10h44 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Apellis, Party City, and Hayward and Encourages Investors to Contact the Firm
22 sept. 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
20 sept. 2023 07h00 HE
|
Bernstein Liebhard LLP
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)?Did you purchase your shares between January 28,...
ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action – APLS
19 sept. 2023 13h15 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between...